Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events. The data were reported at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
“The majority of patients with hepatitis C have viral genotypes 1 and 4, which are generally less responsive to therapy than other genotypes. There is a real need for more effective treatment options - especially for genotype 4, as no oral direct-acting antivirals are approved to treat this patient population”
The primary efficacy endpoint reported in these interim results is the proportion of HCV genotype 1 patients who achieved undetectable viral load (HCV RNA <10 IU/mL) at Weeks 4 and 12 (extended rapid virologic response, or eRVR). Of the 365 patients with HCV genotype 1 in the study, 54% in each of the daclatasvir dose groups (20 mg and 60 mg) achieved eRVR vs. 14% in the control group. The proportion of HCV genotype 1 patients with undetectable viral load at Week 12 was 78% (115/147) and 75% (110/146) in the daclatasvir 20 mg and 60 mg groups, respectively, compared with 43% (31/72) in the control group. Serious adverse events occurred in 7.5% and 7.6% of patients in the daclatasvir 20 mg and 60 mg groups, respectively, and in 6.4% of patients in the control group.
"The majority of patients with hepatitis C have viral genotypes 1 and 4, which are generally less responsive to therapy than other genotypes. There is a real need for more effective treatment options - especially for genotype 4, as no oral direct-acting antivirals are approved to treat this patient population," said Christophe Hézode, MD, Hôpital Henri Mondor, Creteil, France. "The interim results from this Phase IIb study of daclatasvir are encouraging for this compound."
Study Results
Of the 365 patients with HCV genotype 1, 54% in each of the daclatasvir dose groups (20 mg: 79/147; 60 mg: 79/146) and 14% (10/72) in the control group achieved undetectable viral load (HCV RNA <10 IU/mL) at Weeks 4 and 12 (eRVR). The proportion of HCV genotype 1 patients with undetectable viral load at Week 12 (cEVR) was 78% (115/147) and 75% (110/146) in the daclatasvir 20 mg and 60 mg groups, respectively, compared with 43% (31/72) in the control group. At Week 12, the proportion of patients with viral load below the lower limit of quantification (HCV RNA <25 IU/mL) was 84% in each of the daclatasvir dose groups (20 mg: 123/147; 60 mg: 123/146), compared with 53% (38/72) in the control group.
Of the 30 patients with HCV genotype 4, undetectable viral load at Week 12 was achieved in 58% (7/12) and 100% (12/12) of patients in the daclatasvir 20 mg and 60 mg groups, respectively, compared with 50% (3/6) of patients in the control group.
One death was reported in the daclatasvir 20 mg group and was determined by the study investigator to be unrelated to treatment. Discontinuations due to adverse events were similar across the daclatasvir regimens and alfa/RBV control group, with 3.8% (6/159) of patients in the daclatasvir 20 mg group, 5.1% (8/158) in the daclatasvir 60 mg group and 7.7% (6/78) in the control group discontinuing treatment. Serious adverse events occurred in 7.5% (12/159) and 7.6% (12/158) of patients in the daclatasvir 20 mg and 60 mg groups, respectively, and in 6.4% (5/78) of patients in the control group.
The most commonly reported AEs across all groups were fatigue (daclatasvir 20 mg: 55%; daclatasvir 60 mg: 53%; control: 59%) and headache (daclatasvir 20 mg: 42%; daclatasvir 60 mg: 41%; control: 44%). Among commonly reported AEs, a ≥ 10% difference between either dose daclatasvir and placebo was observed with nausea (daclatasvir 20 mg: 35%; daclatasvir 60 mg: 33%; control: 23%) and dry skin (daclatasvir 20 mg: 29%; daclatasvir 60 mg: 25%; control: 19%).
Anemia is a recognized adverse event associated with alfa/RBV treatment of HCV. Erythropoietin was administered to 5.0% (8/159) and 7.0% (11/158) of patients in the daclatasvir 20 mg and 60 mg groups, respectively, and to 3.8% (3/78) of patients in the control group. The use of filgrastim in the study groups was: daclatasvir 20 mg: 1.3% (2/159), daclatasvir 60 mg: 3.2% (5/158), and control: 0% (0/78).
Mediterranean diet may reduce type-2 diabetes risk in fatty liver patients